← Back to Search

Monoclonal Antibodies

B: Elotuzumab + Lenalidomide at 10 mg for Multiple Myeloma

Phase 2
Waitlist Available
Led By Melissa Alsina, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up an average of 8 months
Awards & highlights

Study Summary

This trial will study how well elotuzumab plus lenalidomide works in treating patients with myeloma who have had a relapse.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~an average of 8 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and an average of 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Progression Free Survival (PFS)
Secondary outcome measures
Minimum Response (MR)
Overall Response

Trial Design

2Treatment groups
Active Control
Group I: B: Elotuzumab + Lenalidomide at 10 mgActive Control3 Interventions
Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab. Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule.
Group II: A: Elotuzumab + Lenalidomide at 25 mgActive Control3 Interventions
Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab. Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule.

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
543 Previous Clinical Trials
135,464 Total Patients Enrolled
29 Trials studying Multiple Myeloma
2,095 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbIndustry Sponsor
2,641 Previous Clinical Trials
4,130,046 Total Patients Enrolled
87 Trials studying Multiple Myeloma
29,902 Patients Enrolled for Multiple Myeloma
Melissa Alsina, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute
5 Previous Clinical Trials
150 Total Patients Enrolled
5 Trials studying Multiple Myeloma
150 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
2018. "Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03411031.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top